|
PRECAUTIONS Information for Patients Patients should be instructed to take Neurontin ® only as prescribed. Patients should be advised that Neurontin ® may cause dizziness, somnolence and other symptoms and signs of CNS depression. Accordingly, they should be advised neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on Neurontin ® to gauge whether or not it affects their mental and/ or motor performance adversely. Text Continues Below
Patients who require concomitant treatment with morphine may experience increases in gabapentin concentrations. Patients should be carefully observed for signs of CNS depression, such as somnolence, and the dose of Neurontin ® or morphine should be reduced appropriately (see Drug Interactions). Laboratory Tests Clinical trials data do not indicate that routine monitoring of clinical laboratory parameters is necessary for the safe use of Neurontin ® . The value of monitoring gabapentin blood concentrations has not been established. Neurontin ® may be used in combination with other antiepileptic drugs without concern for alteration of the blood concentrations of gabapentin or of other antiepileptic drugs. Drug Interactions In vitro studies were conducted to investigate the potential of gabapentin to inhibit the major cytochrome P450 enzymes (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) that mediate drug and xenobiotic metabolism using isoform selective marker substrates and human liver microsomal preparations. Only at the highest concentration tested (171 µ g/ mL; 1 mM) was a slight degree of inhibition (14%-30%) of isoform CYP2A6 observed. No inhibition of any of the other isoforms tested was observed at gabapentin concentrations up to 171 µ g/ mL (approximately 15 times the Cmax at 3600 mg/ day). Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs. Page: << Prev | 1 | 2 | 3 | 4 | 5 | Next >>
|
.gif)
